Therapeutic modulation of the liver immune microenvironment
The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Abstract
Inflammation is a hallmark of progressive liver diseases such as chronic viral or immune-mediated hepatitis, alcohol-associated liver disease, and NAFLD. Preclinical and clinical studies have provided robust evidence that cytokines and related cellular stress sensors in innate and adaptive immunity orchestrate hepatic disease processes. Unresolved inflammation and liver injury result in hepatic scarring, fibrosis, and cirrhosis, which may culminate in HCC. Liver diseases are accompanied by gut dysbiosis and a bloom of pathobionts, fueling hepatic inflammation. Anti-inflammatory strategies are extensively used to treat human immune-mediated conditions beyond the liver, while evidence for immunomodulatory therapies and cell therapy–based strategies in liver diseases is only emerging. The development and establishment of novel immunomodulatory therapies for chronic liver diseases has been dampened by several clinical challenges, such as invasive monitoring of therapeutic efficacy with liver biopsy in clinical trials and risk of DILI in several studies. Such aspects prevented advancements of novel medical therapies for chronic inflammatory liver diseases. New concepts modulating the liver immune environment are studied and eagerly awaited to improve the management of chronic liver diseases in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Microbiome analyses of blood and tissues suggest cancer diagnostic approach
Poore, G. D., Kopylova, E., Zhu, Q., Carpenter, C., Fraraccio, S., Wandro, S., Kosciolek, T., Janssen, S., Metcalf, J., Song, S. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2095-1 · Cited by 989
RetractedB-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Gut microbiome and health: mechanistic insights
de Vos, W. M., Tilg, H., Van Hul, M., & Cani, P. D. (2022) · Gut · doi:10.1136/gutjnl-2021-326789 · Cited by 2,388 · cited 1×
“[212] Our gut microbiota holds the potential to develop toward a more host-endangering composition with the generation of so-called pathobionts or evolution of protective species by controlling immune responses.”
BackgroundSelf-citationDepommier, C., Everard, A., Druart, C., Plovier, H., Van Hul, M., Vieira-Silva, S., Falony, G., Raes, J., Maiter, D., Delzenne, N. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0495-2 · Cited by 2,357
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Dinarello, C. A. (2011) · Blood · doi:10.1182/blood-2010-07-273417 · Cited by 2,248 · cited 1×
“[53] These 2 prototypic inflammatory cytokines are rarely detected in the circulation even in case of substantial systemic inflammation and trigger substantial inflammatory symptoms when administered to humans at very low concentrations.[54] NLRP3 and IL-1 family cytokines have been demonstrated to play a key role in…”
BackgroundPlovier, H., Everard, A., Druart, C., Depommier, C., Van Hul, M., Geurts, L., Chilloux, J., Ottman, N., Duparc, T., Lichtenstein, L., et al. (2017) · Nature Medicine · doi:10.1038/nm.4236 · Cited by 2,204
Alterations of the human gut microbiome in liver cirrhosis
Qin, N., Yang, F., Li, A., Prifti, E., Chen, Y., Shao, L., Guo, J., Le Chatelier, E., Yao, J., Wu, L., et al. (2014) · Nature · doi:10.1038/nature13568 · Cited by 2,177
Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium
Derrien, M., Vaughan, E. E., Plugge, C. M., & de Vos, W. M. (2004) · International Journal of Systematic and Evolutionary Microbiology · doi:10.1099/ijs.0.02873-0 · Cited by 2,094 · cited 1×
“This bacterium was initially discovered by Derrien et al,[240] and this bacterium exerts beneficial metabolic effects in rodents and humans.”
BackgroundDao, M. C., Everard, A., Aron-Wisnewsky, J., Sokolovska, N., Prifti, E., Verger, E. O., Kayser, B. D., Levenez, F., Chilloux, J., Hoyles, L., et al. (2016) · Gut · doi:10.1136/gutjnl-2014-308778 · Cited by 1,931
Resolving the fibrotic niche of human liver cirrhosis at single-cell level
Ramachandran, P., Dobie, R., Wilson-Kanamori, J. R., Dora, E. F., Henderson, B. E. P., Luu, N. T., Portman, J. R., Matchett, K. P., Brice, M., Marwick, J. A., et al. (2019) · Nature · doi:10.1038/s41586-019-1631-3 · Cited by 1,784 · cited 1×
“[86,87] Some of the “phenotypic adaptations” of macrophages, mostly discovered in NAFLD/NASH and related animals models, include the contribution to lipid metabolism and lipotoxicity by KC subsets,[88] the evolution of “lipidassociated macrophages” from monocyte-derived macrophages with high TREM2, osteopontin and CD9…”
BackgroundSelf-citation
Cited by
MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
Targher, G., Byrne, C. D., & Tilg, H. (2024) · Gut · doi:10.1136/gutjnl-2023-330595 · Cited by 897
Self-citationWhat defines a healthy gut microbiome?
Van Hul, M., Cani, P. D., Petitfils, C., De Vos, W. M., Tilg, H., & El-Omar, E. M. (2024) · Gut · doi:10.1136/gutjnl-2024-333378 · Cited by 369
Self-citationMeyer, M., Schwärzler, J., Jukic, A., & Tilg, H. (2024) · Biomolecules · doi:10.3390/biom14040476 · Cited by 50
“Tissue-specific inflammation is considered as the driving force in the evolution of organ-specific fibrosis, and it is well established that liver fibrosis defines the prognosis of liver disease [2,3].”
BackgroundSelf-citationAg-driven CD8+ T cell clonal expansion is a prominent feature of MASH in humans and mice
Burtis, A. E. C., DeNicola, D. M. C., Ferguson, M. E., Santos, R. G., Pinilla, C., Kriss, M. S., Orlicky, D. J., Tamburini, B. A. J., Gillen, A. E., & Burchill, M. A. (2025) · Hepatology · doi:10.1097/hep.0000000000000971 · Cited by 30
“[42] However, the development and application of immune modulators in CLD is hindered by the incomplete understanding of both the functions of immune cells in the progression and resolution of disease and the complex interactions between these cell types in the liver.”
Biomimetic Vascularized iPSC‐Hepatocyte Spheroids for Liver Regeneration
Wang, J., Huang, D., Ren, H., & Zhao, Y. (2025) · Advanced Science · doi:10.1002/advs.202405662 · Cited by 13
Metadata
- Authors
- Tilg, H., Adolph, T. E., & Tacke, F.
- Venue
- Hepatology
- Published
- 2023-04-17
- Volume
- 78
- Issue
- 5
- Pages
- 1581-1601
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W4365479183
- Cited by
- 31
- References
- 94
- FWCI
- 4.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic modulation of the liver immune microenvironment. https://app.cochat.ai/papers/10.1097/hep.0000000000000386
- The paper
- Tilg, H., Adolph, T. E., & Tacke, F. (2023). Therapeutic modulation of the liver immune microenvironment. Hepatology. https://doi.org/10.1097/hep.0000000000000386
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.